A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential

Cancer Research

Volumn 61, Issue 5, 2001, Pages 2239-2249

  Masumori, Naoya ^a,b,d   Thomas, Tania Z ^a,b   Chaurand, Pierre ^c   Case, Tom ^a,b   Paul, Manik ^a,b   Kasper, Susan ^a,b,c   Caprioli, Richard M ^c   Tsukamoto, Taiji ^d   Shappell, Scott B ^a,b   Matusik, Robert J ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHROMOGRANIN; PROBASIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IONIZATION; METASTASIS; MOUSE; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANDROGEN-BINDING PROTEIN; ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; PROMOTER REGIONS (GENETICS); PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0035266381     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model
2. Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives
3. Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic, and therapeutic implications
4. Neuroendocrine differentiation in prostatic carcinoma: Recent findings and new concepts
5. Neuroendocrine differentiation in prostatic carcinoma: An update
6. Neuroendocrine differentiation in prostatic carcinoma
7. Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells
8. Restriction of neuroblastoma to the prostate gland in transgenic mice
9. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice
10. Prostate cancer progression, metastasis, and gene expression in transgenic mice
11. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion
12. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
13. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
14. Regulation of a bifunctional mRNA results in synthesis of secreted and nuclear probasin
15. Regulation of prostatic genes: Role of androgens and zinc in gene expression
16. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene
17. Development, progression and androgen-dependence of prostate tumors in transgenic mice: A model for prostate cancer
18. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice
19. Prostate cancer in a transgenic mouse
20. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice
21. Direct profiling of proteins in biological tissues by MALDI mass spectrometry
22. Matrix-assisted ultraviolet-laser desorption/ionization mass spectrometry of biopolymers
23. Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method
24. Protein profiles and identification of high performance liquid chromatography isolated proteins of cancer cell lines using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
25. High grade prostatic intraepithelial neoplasia
26. Altered expression of transforming growth factors during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5′ flanking region fused to SV40 large T antigen
27. Sites of in vivo acetylation in trout testis histone IV
28. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene
29. Tumor suppressor genes
30. Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products
31. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma
32. p53 protein and gene alterations in pathological stage C prostate carcinoma
33. p53 expression in incidental prostatic cancer
34. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate
35. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice
36. Molecular biology of prostatic intraepithelial neoplasia
37. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia
38. Prostatic intraepithelial neoplasia: A premalignant lesion
39. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens
40. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia
41. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes
42. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(I)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations
43. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients
44. Small cell carcinoma of the prostate. I. A clinicopathologic study of 20 cases
45. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate
46. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are post-mitotic cells
47. Bcl-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cells
48. Do neuroendocrine cells in human prostate cancer express androgen receptor?
49. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate
50. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissues
51. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies
52. Small cell anaplastic carcinoma of the prostate: A clinical, pathological and immunohistological study of 27 cases
53. Undifferentiated carcinoma of the prostate with small cell features: Immunohistochemical subtyping and reflections on histogenesis
54. Xenografted small cell undifferentiated cancer of prostate: Possible common origin with prostatic adenocarcinoma
55. Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line
56. The neuroendocrine cell population of the human prostate gland